208 related articles for article (PubMed ID: 22434643)
1. Decreased mucosal sulfide detoxification is related to an impaired butyrate oxidation in ulcerative colitis.
De Preter V; Arijs I; Windey K; Vanhove W; Vermeire S; Schuit F; Rutgeerts P; Verbeke K
Inflamm Bowel Dis; 2012 Dec; 18(12):2371-80. PubMed ID: 22434643
[TBL] [Abstract][Full Text] [Related]
2. Impaired butyrate oxidation in ulcerative colitis is due to decreased butyrate uptake and a defect in the oxidation pathway.
De Preter V; Arijs I; Windey K; Vanhove W; Vermeire S; Schuit F; Rutgeerts P; Verbeke K
Inflamm Bowel Dis; 2012 Jun; 18(6):1127-36. PubMed ID: 21987487
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of butyrate metabolism in the normal colon and in ulcerative colitis: the effects of substrate concentration and carnitine on the β-oxidation pathway.
De Preter V; Geboes KP; Bulteel V; Vandermeulen G; Suenaert P; Rutgeerts P; Verbeke K
Aliment Pharmacol Ther; 2011 Sep; 34(5):526-32. PubMed ID: 21707682
[TBL] [Abstract][Full Text] [Related]
4. Pouchitis, similar to active ulcerative colitis, is associated with impaired butyrate oxidation by intestinal mucosa.
De Preter V; Bulteel V; Suenaert P; Geboes KP; De Hertogh G; Luypaerts A; Geboes K; Verbeke K; Rutgeerts P
Inflamm Bowel Dis; 2009 Mar; 15(3):335-40. PubMed ID: 18942762
[TBL] [Abstract][Full Text] [Related]
5. Decreased mucosal sulfide detoxification capacity in patients with Crohn's disease.
Arijs I; Vanhove W; Rutgeerts P; Schuit F; Verbeke K; De Preter V
Inflamm Bowel Dis; 2013 Apr; 19(5):E70-2. PubMed ID: 23399736
[No Abstract] [Full Text] [Related]
6. Thiolmethyltransferase activity in the human colonic mucosa: implications for ulcerative colitis.
Moore JW; Babidge WJ; Millard SH; Roediger WE
J Gastroenterol Hepatol; 1997 Oct; 12(9-10):678-84. PubMed ID: 9407333
[TBL] [Abstract][Full Text] [Related]
7. Antagonistic effects of sulfide and butyrate on proliferation of colonic mucosa: a potential role for these agents in the pathogenesis of ulcerative colitis.
Christl SU; Eisner HD; Dusel G; Kasper H; Scheppach W
Dig Dis Sci; 1996 Dec; 41(12):2477-81. PubMed ID: 9011461
[TBL] [Abstract][Full Text] [Related]
8. Genes associated with intestinal permeability in ulcerative colitis: changes in expression following infliximab therapy.
Toedter G; Li K; Sague S; Ma K; Marano C; Macoritto M; Park J; Deehan R; Matthews A; Wu GD; Lewis JD; Arijs I; Rutgeerts P; Baribaud F
Inflamm Bowel Dis; 2012 Aug; 18(8):1399-410. PubMed ID: 22223479
[TBL] [Abstract][Full Text] [Related]
9. The colonic epithelium in ulcerative colitis: an energy-deficiency disease?
Roediger WE
Lancet; 1980 Oct; 2(8197):712-5. PubMed ID: 6106826
[TBL] [Abstract][Full Text] [Related]
10. Differentiation of the roles of sulfide oxidase and rhodanese in the detoxification of sulfide by the colonic mucosa.
Wilson K; Mudra M; Furne J; Levitt M
Dig Dis Sci; 2008 Jan; 53(1):277-83. PubMed ID: 17551834
[TBL] [Abstract][Full Text] [Related]
11. Butyrate enemas do not affect human colonic MUC2 and TFF3 expression.
Hamer HM; Jonkers DM; Renes IB; Vanhoutvin SA; Kodde A; Troost FJ; Venema K; Brummer RJ
Eur J Gastroenterol Hepatol; 2010 Sep; 22(9):1134-40. PubMed ID: 20461009
[TBL] [Abstract][Full Text] [Related]
12. Colonic sulfide in pathogenesis and treatment of ulcerative colitis.
Roediger WE; Moore J; Babidge W
Dig Dis Sci; 1997 Aug; 42(8):1571-9. PubMed ID: 9286219
[TBL] [Abstract][Full Text] [Related]
13. The Anti-inflammatory Immune Regulation Induced by Butyrate Is Impaired in Inflamed Intestinal Mucosa from Patients with Ulcerative Colitis.
Magnusson MK; Isaksson S; Öhman L
Inflammation; 2020 Apr; 43(2):507-517. PubMed ID: 31797122
[TBL] [Abstract][Full Text] [Related]
14. Mucosal enzyme activity for butyrate oxidation; no defect in patients with ulcerative colitis.
Allan ES; Winter S; Light AM; Allan A
Gut; 1996 Jun; 38(6):886-93. PubMed ID: 8984028
[TBL] [Abstract][Full Text] [Related]
15. Sulfide-detoxifying enzymes in the human colon are decreased in cancer and upregulated in differentiation.
Ramasamy S; Singh S; Taniere P; Langman MJ; Eggo MC
Am J Physiol Gastrointest Liver Physiol; 2006 Aug; 291(2):G288-96. PubMed ID: 16500920
[TBL] [Abstract][Full Text] [Related]
16. Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: a possible molecular pathway of mucosal healing in ulcerative colitis.
Ierardi E; Giorgio F; Zotti M; Rosania R; Principi M; Marangi S; Della Valle N; De Francesco V; Di Leo A; Ingrosso M; Panella C
J Clin Pathol; 2011 Nov; 64(11):968-72. PubMed ID: 21945924
[TBL] [Abstract][Full Text] [Related]
17. Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C.
Magnusson MK; Strid H; Isaksson S; Bajor A; Lasson A; Ung KA; Öhman L
J Crohns Colitis; 2015 Jan; 9(1):56-65. PubMed ID: 25518051
[TBL] [Abstract][Full Text] [Related]
18. Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis.
Chapman MA; Grahn MF; Boyle MA; Hutton M; Rogers J; Williams NS
Gut; 1994 Jan; 35(1):73-6. PubMed ID: 8307454
[TBL] [Abstract][Full Text] [Related]
19. Impaired detoxication of hydrogen sulfide in ulcerative colitis?
Picton R; Eggo MC; Langman MJ; Singh S
Dig Dis Sci; 2007 Feb; 52(2):373-8. PubMed ID: 17216575
[TBL] [Abstract][Full Text] [Related]
20. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy.
Caprioli F; Bosè F; Rossi RL; Petti L; Viganò C; Ciafardini C; Raeli L; Basilisco G; Ferrero S; Pagani M; Conte D; Altomare G; Monteleone G; Abrignani S; Reali E
Inflamm Bowel Dis; 2013; 19(4):729-39. PubMed ID: 23448791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
